NPTX2 and Alzheimer disease: Both the two secreted NPTX1 and NPTX2 and the transmembrane receptor NPTXR have been found in several studies to be decreased in CSF in AD compared with controls [14, 38–41] and appear to be markers of disease progression in AD [42–44].